HSV thymidine kinase gene therapy - Avigen
Latest Information Update: 07 Sep 2005
At a glance
- Originator Avigen
- Class Gene therapies
- Mechanism of Action Thymidine kinase stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Glioma